Based on the 2025 Journal of Clinical Investigation commentary on emerging fungal vaccine science
Why fungal vaccines matter
Fungal infections remain a major global health problem, causing an estimated 3.8 million deaths per year. Yet despite this huge burden, there are currently no licensed vaccines to prevent or treat fungal disease.
For people living with aspergillosis—including chronic pulmonary aspergillosis (CPA), allergic bronchopulmonary aspergillosis (ABPA), severe asthma with fungal sensitisation (SAFS), and Aspergillus bronchitis—this gap is very real.
Treatments often involve long-term antifungal medications, steroids, or biologics, and symptoms may recur despite therapy.
A new scientific commentary in the Journal of Clinical Investigation highlights major progress in fungal vaccine research and suggests that vaccines may become important tools for both prevention and treatment in the future.
A new breakthrough: the Eng2 fungal antigen
Researchers studying serious fungal infections in North and South America have identified an enzyme called endoglucanase-2 (Eng2) that triggers a strong immune response:
-
It protected mice from Blastomyces, Histoplasma, and Coccidioides infections.
-
People recovering from these infections show memory CD4 T-cell responses to Eng2.
This suggests two important possibilities:
1. A preventive vaccine
A future vaccine could reduce the risk of developing serious fungal infections—especially in people with weakened immune systems or chronic lung disease.
2. A therapeutic vaccine
Unlike most vaccines, a therapeutic vaccine would be given after infection to support the immune system and help clearance—similar to how post-exposure rabies or hepatitis A vaccines work.
This second application is particularly relevant to aspergillosis.
Why fungal vaccines may be especially useful in Aspergillus disease
Although the study did not focus on Aspergillus specifically, the commentary highlights several reasons why Aspergillus vaccines are scientifically realistic.
1. Fungi are surprisingly easy to vaccinate against in animal studies
Many fungal antigens have already shown strong protective effects in experimental models.
Unlike viruses such as HIV or tuberculosis—where vaccines are extremely difficult—fungal pathogens often respond well to:
-
Antibody-based immunity
-
T-cell immunity
Both would be valuable in Aspergillus-related disease.
2. Aspergillosis mainly affects people with weakened or inflamed lungs
This makes it exactly the kind of disease where a vaccine could:
-
Reduce fungal burden in the airways
-
Decrease inflammation
-
Support existing treatments
-
Reduce flare-ups and symptoms
3. A therapeutic vaccine may arrive before a preventive vaccine
Chronic fungal diseases (especially CPA and Aspergillus bronchitis) develop slowly and persist for months or years.
This gives time for a vaccine to stimulate the immune system during ongoing treatment.
A therapeutic vaccine could:
-
Enhance the effect of antifungal drugs
-
Reduce the amount of fungus growing in cavities or bronchiectatic airways
-
Lower inflammation and antibody levels
-
Potentially reduce the need for long-term steroids or biologics in ABPA
4. A combination (“multivalent”) vaccine is possible
The Eng2 research shows that one antigen may not protect against all fungal species.
However, a “cocktail” vaccine—using several fungal proteins—could cover multiple fungi, including Aspergillus.
What this could mean for different aspergillosis conditions
For CPA (Chronic Pulmonary Aspergillosis)
A therapeutic vaccine might help:
-
Reduce fungal load in cavities
-
Improve long-term control
-
Support patients who can’t tolerate antifungals
-
Reduce reliance on prolonged azole therapy
For ABPA (Allergic Bronchopulmonary Aspergillosis)
ABPA is an allergic reaction rather than a true infection.
But reducing the amount of Aspergillus in the airways could:
-
Decrease IgE levels
-
Reduce flare frequency
-
Lower the need for steroids
-
Improve asthma control
For SAFS and Aspergillus bronchitis
A vaccine could potentially:
-
Reduce airway colonisation
-
Improve symptom control
-
Reduce the cycle of infection → inflammation → airway damage
What this means for patients today
It is important to be clear:
There is no Aspergillus vaccine available yet.
However, the science is moving faster than ever.
The commentary highlights:
-
Multiple experimental vaccines have already worked in animals
-
Some fungal vaccines have reached early human trials
-
mRNA technology (used for COVID vaccines) could accelerate development
-
High-risk groups—including people with chronic lung disease—would be early candidates
For the aspergillosis community, this research is a major step forward, offering hope for safer and more effective long-term management.
For clinicians: why this matters now
Non-specialist clinicians may want to be aware that:
-
Vaccine-based immunotherapy may become part of fungal disease management
-
Therapeutic vaccines could work alongside antifungals, rather than replacing them
-
Advances in antigen identification (e.g., Eng2) create realistic pathways for Aspergillus-specific research
-
Patient groups with chronic fungal or allergic disease may benefit significantly from immunological boosting
As fungal disease continues to rise worldwide, vaccination represents a promising future tool in managing both invasive and chronic fungal illnesses.
Looking ahead
While fungal vaccines are “so needed, so feasible, and yet still far off,” the momentum is building.
For people living with aspergillosis—often for many years—the possibility of vaccines offers genuine hope for:
-
Better control
-
Improved quality of life
-
Reduced treatment burden
-
Less risk of long-term complications
This new research marks an important step on that journey.
Latest News posts
News archive